- Home
- BMRC vs AUTL Comparison
BMRC vs AUTL Comparison
Compare BMRC & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BMRC | AUTL |
|---|---|---|
| Founded | 1989 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 424.3M | 433.8M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | BMRC | AUTL |
|---|---|---|
| Price | $25.98 | $1.95 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | ★ $28.00 | $8.67 |
| AVG Volume (30 Days) | 91.5K | ★ 2.7M |
| Earning Date | 01-26-2026 | 11-12-2025 |
| Dividend Yield | ★ 3.81% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.62 | N/A |
| Revenue | ★ $96,957,000.00 | $51,128,000.00 |
| Revenue This Year | $63.10 | $669.49 |
| Revenue Next Year | $15.24 | $91.53 |
| P/E Ratio | $42.47 | ★ N/A |
| Revenue Growth | 63.31 | ★ 406.67 |
| 52 Week Low | $19.14 | $1.11 |
| 52 Week High | $28.48 | $2.70 |
Technical Indicators
Market Signals| Indicator | BMRC | AUTL |
|---|---|---|
| Relative Strength Index (RSI) | 40.34 | 64.91 |
| Support Level | $25.60 | $1.77 |
| Resistance Level | $26.90 | $2.05 |
| Average True Range (ATR) | 0.78 | 0.12 |
| MACD | -0.18 | 0.02 |
| Stochastic Oscillator | 8.96 | 77.67 |
Price Performance
Historical ComparisonAbout BMRC Bank of Marin Bancorp
Bank of Marin Bancorp is a United States-based bank holding company. It conducts business through its wholly-owned subsidiary. The Bank provides a wide range of financial services to customers such as professionals, small and middle-market businesses, and individuals residing in Marin, Sonoma, Napa, San Francisco, Alameda, Contra Costa, San Mateo counties and others. The majority of its revenue comes from interest income.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.